Prashant V Nigwekar1, Anuj Kumar1, Vikram V Padbidri2, Amlan Choudhury3, Amol B Chaudhari4, Prasad S Kulkarni5. 1. Pravara Institute of Medical Sciences, Loni, India. 2. Jehangir Hospital, Pune, India. 3. KPC Medical College, Kolkata, India. 4. Serum Institute of India Pvt. Ltd, 212/2, Hadapsar, Pune, India. amol.chaudhari@seruminstitute.com. 5. Serum Institute of India Pvt. Ltd, 212/2, Hadapsar, Pune, India.
Abstract
INTRODUCTION AND AIM: A trivalent live attenuated influenza vaccine (Nasovac-S®) was developed and licensed in India. A phase 4 study was conducted to assess safety. METHODOLOGY: This non-randomized, open-label, single-arm study among individuals ≥ 2 years of age involved administration of 0.5 mL of Nasovac-S intranasally, with a 1-month follow-up after vaccination. Adverse events (AEs) were collected via structured diaries. RESULTS: Among 500 vaccinated subjects, 160 were between 2 and 17 years of age, 240 were 18-49 years old and 100 were 50 years and older. A total of 533 solicited reactions were reported. The majority of these reactions were mild, and almost all of them resolved without any sequelae. A total of 20% of subjects reported at least one local solicited reaction, and 23% reported at least one systemic solicited reaction. None of the 45 unsolicited AEs reported by 37 subjects (7.4%) were causally related to the study vaccine. CONCLUSIONS: The data from the study adds to the existing safety database of Nasovac-S. REGISTRY: Clinical Trials Registry of India (CTRI/2015/08/006074).
INTRODUCTION AND AIM: A trivalent live attenuated influenza vaccine (Nasovac-S®) was developed and licensed in India. A phase 4 study was conducted to assess safety. METHODOLOGY: This non-randomized, open-label, single-arm study among individuals ≥ 2 years of age involved administration of 0.5 mL of Nasovac-S intranasally, with a 1-month follow-up after vaccination. Adverse events (AEs) were collected via structured diaries. RESULTS: Among 500 vaccinated subjects, 160 were between 2 and 17 years of age, 240 were 18-49 years old and 100 were 50 years and older. A total of 533 solicited reactions were reported. The majority of these reactions were mild, and almost all of them resolved without any sequelae. A total of 20% of subjects reported at least one local solicited reaction, and 23% reported at least one systemic solicited reaction. None of the 45 unsolicited AEs reported by 37 subjects (7.4%) were causally related to the study vaccine. CONCLUSIONS: The data from the study adds to the existing safety database of Nasovac-S. REGISTRY: Clinical Trials Registry of India (CTRI/2015/08/006074).
Authors: Timo Vesikari; Aino Karvonen; Tiina Korhonen; Kati Edelman; R Vainionpää; Aimo Salmi; Melanie K Saville; Iksung Cho; Ahmad Razmpour; Ruth Rappaport; Robert O'Neill; Alice Georgiu; William Gruber; Paul M Mendelman; Bruce Forrest Journal: Pediatr Infect Dis J Date: 2006-07 Impact factor: 2.129
Authors: Robert B Belshe; Kathryn M Edwards; Timo Vesikari; Steven V Black; Robert E Walker; Micki Hultquist; George Kemble; Edward M Connor Journal: N Engl J Med Date: 2007-02-15 Impact factor: 91.245
Authors: Justin R Ortiz; Doli Goswami; Kristen D C Lewis; Amina Tahia Sharmeen; Moshtaq Ahmed; Mustafizur Rahman; Mohammed Z Rahman; Jodi Feser; Kathleen M Neuzil; W Abdullah Brooks Journal: Vaccine Date: 2015-04-24 Impact factor: 3.641
Authors: Tom Jefferson; Alessandro Rivetti; Anthony Harnden; Carlo Di Pietrantonj; Vittorio Demicheli Journal: Cochrane Database Syst Rev Date: 2008-04-16
Authors: Jördis J Ott; Janna Klein Breteler; John S Tam; Raymond C W Hutubessy; Mark Jit; Michiel R de Boer Journal: Hum Vaccin Immunother Date: 2013-05-31 Impact factor: 3.452